Gastric and gastroesophageal junction cancers Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-highest leading cause of cancer mortality.1 Nearly one million new patients were diagnosed with gastric cancer in 2022, with approximately 660,000 deaths reported globally.1 In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.3 In 2024, there were roughly 43,000 drug-treated patients in the US, EU and Japan in early-stage and locally advanced gastric or GEJ cancer.2 Approximately 62,000 patients in these regions are expected to be newly diagnosed in this setting by 2030.4
GEJ cancer is a type of gastric cancer that arises from and spans the area where the oesophagus connects to the stomach.5
Disease recurrence is common in patients with resectable gastric cancer despite undergoing surgery with curative intent and treatment with neoadjuvant/adjuvant chemotherapy.6 Approximately one in four patients with gastric cancer who undergo surgery develop recurrent disease within one year, and the five-year survival rate remains poor, with less than half of patients alive at five years.6-7
MATTERHORN MATTERHORN is a randomised, double-blind, placebo-controlled, multi-centre, global Phase III trial evaluating Imfinzi as perioperative treatment for patients with resectable Stage II-IVA gastric and GEJ cancers. Perioperative therapy includes treatment before and after surgery, also known as neoadjuvant/adjuvant therapy. In the trial, 948 patients were randomised to receive a 1500mg fixed dose of Imfinzi plus FLOT chemotherapy or placebo plus FLOT chemotherapy every four weeks for two cycles prior to surgery. This was followed by Imfinzi or placebo every four weeks for up to 12 cycles after surgery (including two cycles of Imfinzi or placebo plus FLOT chemotherapy and 10 additional cycles of Imfinzi or placebo monotherapy).
In the MATTERHORN trial, the primary endpoint is EFS, defined as time from randomisation until the date of one of the following events (whichever occurred first): RECIST (version 1.1, per blinded independent central review assessment) progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period; RECIST progression/recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Key secondary endpoints include pathologic complete response rate, defined as the proportion of patients who have no detectable cancer cells in resected tumour tissue following neoadjuvant therapy, and OS. The trial enrolled participants in 176 centres in 20 countries, including in the US, Canada, Europe, South America and Asia.
Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.
In GI cancer, Imfinzi is approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer (BTC) and in combination with Imjudo (tremelimumab) in unresectable hepatocellular carcinoma (HCC). Imfinzi is also approved as a monotherapy in unresectable HCC in Japan and the EU.
In addition to its indications in GI cancers, Imfinzi is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy (CRT). Additionally, Imfinzi is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of Imjudo and chemotherapy for the treatment of metastatic NSCLC. Imfinzi is also approved for limited-stage small cell lung cancer (SCLC) in patients whose disease has not progressed following concurrent platinum-based CRT; and in combination with chemotherapy for the treatment of extensive-stage SCLC.
Perioperative Imfinzi in combination with neoadjuvant chemotherapy is approved in the US, EU, Japan and other countries for patients with muscle-invasive bladder cancer based on results from the NIAGARA Phase III trial. Additionally, in May 2025, Imfinzi added to Bacillus Calmette-Guérin induction and maintenance therapy met the primary endpoint of disease-free survival for patients with high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial.
Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease only in the US and EU). Imfinzi in combination with chemotherapy followed by Lynparza (olaparib) and Imfinzi is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in the EU and Japan.
Since the first approval in May 2017, more than 414,000 patients have been treated with Imfinzi. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, bladder cancer, breast cancer, ovarian cancer and several GI cancers.
AstraZeneca in GI cancers AstraZeneca has a broad development programme for the treatment of GI cancers across several medicines and a variety of tumour types and stages of disease. In 2022, GI cancers collectively represented approximately 5 million new cancer cases leading to approximately 3.3 million deaths.8
Within this programme, the Company is committed to improving outcomes in gastric, liver, biliary tract, oesophageal, pancreatic, and colorectal cancers.
In addition to its indications in BTC and HCC, Imfinzi is being assessed in combinations, including with Imjudo, in liver, oesophageal and gastric cancers in an extensive development programme spanning early to late-stage disease across settings.
Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), is approved in the US and several other countries for HER2-positive advanced gastric cancer. Enhertu is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Lynparza, a first-in-class PARP inhibitor, is approved in the US and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. inside the US and Canada).
The Company is also assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in combination with chemotherapy as an adjuvant therapy in BTC, in combination with bevacizumab with or without Imjudo as a 1st-line treatment in patients with advanced HCC, and as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic gastric and GEJ cancers. Rilvegostomig is also being evaluated in combination with Enhertu in previously untreated, HER2-expressing, locally advanced or metastatic BTC.
AstraZeneca is advancing multiple modalities that provide complementary mechanisms for targeting Claudin 18.2, a promising therapeutic target in gastric cancer. These include sonesitatug vedotin, a potential first-in-class ADC licensed from KYM Biosciences Inc., currently in Phase III development; AZD5863, a novel Claudin 18.2/CD3 T-cell engager bispecific antibody licensed from Harbour Biomed in Phase I development; and AZD4360, an antibody drug conjugate, currently being evaluated in a Phase I/II trial in patients with advanced solid tumours.
In early development, AstraZeneca is developing C-CAR031 / AZD7003, a Glypican 3 (GPC3) armoured CAR T, in HCC. C-CAR031 / AZD7003is being co-developed with AbelZeta in China where it is under evaluation in an IIT.
AstraZeneca in immuno-oncology (IO) AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours.
AstraZeneca strives to redefine cancer care and help transform outcomes for patients with Imfinzi as a monotherapy and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers.
AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure.
AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
More than 350 staff at London Transit were due to walk out on 26, 27 and 28 November
Three more days of strike action by west London bus workers have been postponed pending further talks next week.
More than 350 staff at London Transit were due to walk out on 26, 27 and 28 November. Drivers, engineers and store workers based at the Westbourne Park depot are unhappy with a below-inflation pay rise offered by the company’s parent firm, First Bus London.
The same Unite union members previously took part in industrial action on 14, 17 and 18 November.
First Bus London said: “We’re pleased that, following positive discussions, the planned strike action has been cancelled and that further talks with Unite will continue.”
It added: “Industrial action causes significant disruption for Londoners who rely on our services and for our colleagues, so we welcome this outcome.”
Unite has agreed to attend a meeting with conciliation service Acas and London Transit on 2 December in an effort to resolve the dispute.
Transport for London confirmed that services were expected to run as normal in the coming days.
‘Utter disregard’
Unite previously requested an above-inflation pay offer with full back pay for all employees, demands it says have not yet been met.
Unite’s general secretary Sharon Graham said: “This is disgraceful behaviour from a company making millions from London bus passengers.
“It shows an utter disregard for its workers and the hard work they do day in, day out.
“Our members won’t stand for such behaviour and Unite will back them all the way in this dispute with a company that has a history of anti-worker behaviour.”
Routes affected during the strike would have included 13, 23, 31, N31, 218, 295 and 452.
WASHINGTON — Commodity Futures Trading Commission Acting Chairman Caroline D. Pham is seeking nominations for the CFTC CEO Innovation Council. The deadline for submissions is December 8. Under Acting Chairman Pham’s leadership, the CFTC has led rapid advancements on innovation and market structure, including the Crypto CEO Forum, prediction markets, perpetual contracts, and 24/7 trading. The CFTC’s Crypto Sprint to implement the President’s Working Group on Digital Asset Markets report recommendations is targeted to continue through August 2026 and includes listed spot crypto trading, tokenized collateral and stablecoins, and rulemaking to enable the use of blockchain technology and market infrastructure.
“The U.S. is leading a new era in market structure, and the CFTC is at the forefront of this renaissance accelerated by innovation and technology,” said Acting Chairman Pham. “The CFTC stands ready to carry out our mission over expanded markets and products, including crypto and digital assets, and ensure our markets remain vibrant and resilient while protecting all participants. In order to hit the ground running, it is critical that the CFTC drives public engagement with the support of expert industry leaders and visionaries who are building the future. That is why today I am calling upon CEOs to join us in shaping responsible regulations that will lay the foundation for America’s Golden Age of Innovation.”
Acting Chairman Pham invites members of the public to nominate individuals for the CEO Innovation Council and propose potential topics to prioritize. Each nomination submission should include relevant information about the nominee, such as the individual’s name, title, and organizational affiliation as well as information that supports the individual’s qualifications for the CEO Innovation Council. The submission should also include suggestions for potential topics to prioritize as well as the name and email or mailing address of the person nominating the individual. Submission of a nomination is not a guarantee of selection for the CEO Innovation Council.
CEO Innovation Council nominations and potential topics should be emailed to [email protected]. Please use the subject ‘‘CEO Innovation Council Nomination’’ for submissions.
Just what an embattled chancellor needs on the eve of a tax-raising budget: a leading retailer upping its profits forecast and singing about the joys of the UK economy.
Unfortunately, only the first bit is true. Kingfisher, owner of B&Q and Screwfix (and similar businesses in France and Poland), raised its profit expectations for its current financial year from £480m-£540m to £540m-£570m.
But it definitely didn’t ooze confidence in the UK outlook. Rather, Kingfisher noted “softening market conditions” and added: “We continue to be mindful of inflation, uncertainty ahead of the autumn budget and the softening labour market.”
In other words, the group is saying its improvement in the profits department is a self-help job, which is fair. Like-for-like sales in the UK in the last quarter were up 3%. It is winning market share in the UK (where it helps that Homebase went into administration a year ago), grabbing a bigger slice of the professional “trade” market and improving its e-commerce game. The slick Screwfix operation continues to be streets ahead of its direct rivals. Meanwhile, the recently troubled French operation (Castorama and Brico Dépôt) is being restructured, which helped slightly to off-set local “weak consumer sentiment” that sounds several degrees worse than in the UK.
Take a step back and Kingfisher’s progress can be regarded as a parable of the retail scene in two ways. First, it is proof that a basically well managed operator in a strong competitive position can prosper even under subdued economic conditions. For other examples, think Tesco, Sainsbury’s and Next. All have been great shares to own in the 12 months since Rachel Reeves’s last budget, never mind the increase in employers’ national insurance and the rest of it.
The other aspect is more nuanced. On one hand, the ridiculously long and chaotic build-up to the budget has plainly sapped consumer confidence – a CBI distributive trades survey on Tuesday confirmed what we already knew. On the other hand, there still remains a basic level of resilience if Kingfisher is a guide. “Softening” is not the same as outright soft. For that, give thanks for four cuts in interest rates since last October’s budget. Lower mortgage costs matter particularly in DIY businesses for big-ticket items such as kitchens and bathrooms.
So one can – just about – sketch out an optimistic scenario for consuming-facing companies in which Reeves avoids inflation-raising howlers such as last year’s NICs rises and clears the way for the Bank of England to cut interest rates faster. The gilts market has half-bought that story in recent weeks as yields have fallen from their scary September highs.
skip past newsletter promotion
after newsletter promotion
The alternative, though, is not good from businesses’ point of view. The prospect of rate cuts is virtually the only big-picture factor running in their favour as they contemplate pressure on wages and fixed costs. Remove lower borrowing costs and there’s little to stop softening conditions turning soggy very quickly. Kingfisher, to repeat, can handle most outcomes. But consumer sentiment across the retail landscape looks fragile.
Agentic AI trained on the judgement of elite security analysts automates high-impact workflows to keep public sector defenders ahead of AI-accelerated threats
AUSTIN, Texas – November 25, 2025 – CrowdStrike (NASDAQ: CRWD) today announced that CrowdStrike® Charlotte AI has achieved Federal Risk and Authorization Management Program (FedRAMP) High Authorization. With this designation, CrowdStrike is transforming public sector defense for the AI era, automating the time-consuming tasks better suited for machines. Trained on the judgement of elite security analysts, Charlotte AI is now available to federal, state, and local agencies through the Falcon® platform in GovCloud, elevating defenders from alert handlers to orchestrators of the agentic SOC.
“Government agencies face some of the most advanced cyber threats in the world and demand the highest level of protection,” said Michael Sentonas, president of CrowdStrike. “By bringing Charlotte AI to GovCloud, security teams can automate high-impact workflows with the expertise of the industry’s best SOC operators, stopping sophisticated threats at the speed of AI with precision and control.”
The public sector is under relentless attack, with adversaries weaponizing AI to accelerate every stage of the threat chain and collapse the defender’s window to act. Trained on years of real-world decisions from Falcon® Complete and incident response engagements, Charlotte AI thinks, reasons, and acts like an elite analyst at machine speed, always under defender control. This flips time in defenders’ favor, eliminating high-friction tasks and enabling analysts to focus on the strategic decisions that strengthen security.
Delivered through the FedRAMP-authorized Falcon platform, the first Charlotte AI capabilities available in GovCloud include:
Detection Triage Agent: Triages security detections with over 98% accuracy1, eliminating more than 40 hours of manual work per week on average2 to scale SOC operations and accelerate response to the most critical threats.
Charlotte AI Actions in Falcon Fusion SOAR: Enables analysts to use a drag-and-drop interface to embed AI reasoning into playbooks. For example, determining device containment based on company policies and generating tailored communications for executives, technical teams, and customers, with automatic translation for global reach.
The FedRAMP High Authorization validates that Charlotte AI meets FedRAMP’s most rigorous security and compliance standards, providing data confidentiality, integrity, and availability across mission-critical U.S. government operations.
To learn more about Charlotte AI, visit here. To learn more about CrowdStrike’s ongoing commitment to meeting the highest independent and government-led cybersecurity and information management standards, visit the CrowdStrike Compliance and Certification Page.
About CrowdStrike
CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.
Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.
Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.
CrowdStrike: We stop breaches.
Learn more: https://www.crowdstrike.com/
Follow us: Blog | X | LinkedIn | Instagram
Start a free trial today: https://www.crowdstrike.com/trial
1Accuracy rating is a measure of Charlotte AI triage decisions that match the expert decisions from the CrowdStrike Falcon Complete Next-Gen MDR team.
2Calculated by multiplying the average number of alerts triaged by Charlotte AI by a 5-minute triage time per alert as estimated by the Falcon Complete team. Individual results may vary based on factors such as total alert volume.
Built on a strong, two-year partnership with Google Cloud, this recognition confirms Valeo’s pioneering position as it advances into the AI era.
November 25, 2025 — Paris, France — At the Adopt AI Summit held by Artefact, Valeo CEO Christophe Périllat has been honored by the “CEO of the Year” Award by Google Cloud in France. This title serves as a powerful recognition of Périllat’s bold, systematic strategy to embed artificial intelligence across the entire global mobility technology leader. The award celebrates a forward-looking vision pivotal in shaping the future of mobility, demonstrating how Valeo is translating the vast opportunities of AI into concrete, industry-leading solutions.
Christophe Périllat, CEO of Valeo, said: “We see AI as the ultimate productivity game-changer, particularly for complex R&D cycles. The companies that deploy it with precision will pull ahead. Our teams have fully embraced this strategy, building on more than two decades of AI experience. We are not just experimenting — we are leveraging a profound historical advantage to deliver cutting-edge, effective solutions that others are only now beginning to explore.”
Decades of Vision: Valeo’s 20-Year AI Advantage
At Valeo, the application of AI is a long-term strategy that started more than 20 years ago. Over the course of years, Valeo developed neural networks and deep learning to understand the vehicle’s environment and develop solutions for safer and more automated mobility. Today, the Group leverages AI at every stage, from research and development, factories to product design with more than 9,000 software and system engineers, and 200 AI experts.
The Generative Leap: 25% of Certified Code is Now AI-Generated
Through a long-term partnership with Google Cloud, the Group deploys its coding assistant and trains key users for them to coach and support local teams. By the end of 2024, all software engineers were trained and equipped with Generative AI tools, and today more than 25% of Valeo’s certified automotive code is AI-generated, marking a massive increase from 0% just 16 months ago. The company also deployed Generative AI to greatly simplify the analysis of technical specifications. Through other partnerships, Valeo is also working on the automatic design of mechanical parts and of PCBs.
This significant acceleration is further bolstered by internal initiatives focused on hands-on innovation. At the beginning of its internal transformation, in 2024, Valeo organized its first hackathon focusing on generative AI through a joint partnership with Google Cloud and Artefact. During this hackathon, 16 teams participated in the training sessions with data scientists from Artefact and experts from Google Cloud, and more than 120 Valeo employees leveraged generative AI to advance innovative ideas into the creation of minimum viable products (MVP). Most of these ideas are now being implemented, as the hackathon was the foundation of Valeo’s AI4all program, which has led to the deployment of 84 AI agents to boost productivity within the company.
Valeo.AI: Driving Reliability and Safety in Complex Road Scenarios
Valeo’s long-term AI commitment is driven by Valeo.AI, the first global AI research center dedicated specifically to automotive applications, founded in 2017. Connected with the academic world, the center pioneers research in assisted and autonomous driving. Its mission: to overcome key challenges like enhancing Advanced Driving Assistance Systems (ADAS) reliability in complex scenarios (e.g., adverse weather or abnormal road conditions). Valeo.AI focuses on sensor fusion, data-efficient learning, and developing dependable, explainable AI models to ensure safer, more efficient, and robust autonomous travel worldwide.
Christophe Périllat receives the “CEO of the Year” award from Isabelle Fraine, Managing Director of Google Cloud France.
Just in time for Cyber Monday 2025, Gap Inc. customers will see something new when they shop online — experiences powered by artificial intelligence that make it easier to discover styles they love, find the right fit, and shop seamlessly across our family of brands.
At Gap Inc., we’re embracing AI to reimagine what’s possible in retail — from how our teams design products to how customers experience them. And starting this holiday shopping season, we’re using new AI-powered tools to make the shopping experience more seamless, more personalized, and more fun for our customers.
Whether online or in stores, AI is helping us remove friction, spark creativity, and inspire confidence in every interaction. By combining our deep retail expertise with the latest AI tools, we’re able to better understand what our customers want, anticipate their needs, and deliver experiences that feel uniquely tailored to them.
A More Personal Way to Shop
Across our brand sites, customers will find new AI-powered features that make shopping faster, smarter, and more inspiring:
Trend based curations: Intelligent edits like Gap’s Fall Trend Edit and Banana Republic’s Fall Essentials use AI to highlight the styles, colors, and looks that are trending at the speed of culture.
Smarter Product Recommendations: New tools such as “Wear It With,” “You Might Also Like,” and “Customers Also Viewed” offer more intuitive product pairings to inspire complete looks.
AI-Powered Customer Care: Our digital assistant, available through “Chat with Us” on brand sites and in the mobile app, helps customers manage returns, payments, order tracking, and more — any time, on any device.
Intelligent Fit: Now available with Gap and Old Navy denim bottoms provides customers recommended sizes based on key body measurements.
Customers can also discover Gap Inc. products through emerging AI-powered platforms like daydream.ing, helping customers find their style and connect back to our brand sites to shop.
Behind The Scenes
These retail experiences are powered by the same AI-driven workflows that are transforming how our teams create:
Designers now use generative AI to move from concept sketches to photorealistic product renders in minutes — accelerating creativity and shortening the path from idea to launch.
In our offices, we’re embedding AI experimentation into our culture. Employees across Gap Inc. are adopting new AI tools that boost storytelling, planning, and design.
These innovations are being built on a unified, AI-powered platform developed in collaboration with Google Cloud and other technology partners. This flexible infrastructure allows teams to test, learn, and scale new ideas across design, commerce, and customer experience.
From product creation to customer care, our approach to AI is bringing more personalization, more creativity, and more connection to every shopping experience.
– Sven Gerjets
About Gap Inc.
Gap Inc., a purpose-driven house of iconic brands, is the largest specialty apparel company in America. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories, and lifestyle products for men, women and children available worldwide through company-operated and franchise stores, and e-commerce sites. Since 1969, Gap Inc. has created products and experiences that shape culture, while doing right by employees, communities and the planet through its commitment to bridge gaps to create a better world. For more information, please visit www.gapinc.com.
Don’t miss out on the latest Gap Inc. news! Sign-up to get email alerts about news on Gap Inc. and our brands.
Apex Logistics signed an agreement to acquire the majority of shares of Andes Integración Logística. The transaction will enhance Apex Logistics’ offering in Latin America and support its strategic development goals.
Andes Integración Logística, established in 2008, offers a comprehensive range of logistics services, including international air and sea freight, land transportation, warehousing, and distribution. Over the past 17 years, the company has experienced significant growth and today provides services in Chile, Colombia, Argentina, Peru, Paraguay, Uruguay, Bolivia, the USA, and China.
As one of the leading logistics providers in South America, Andes Integración Logística handles over 90,000 TEUs (twenty-foot equivalent unit) of ocean shipping containers and 40,000 tons of airfreight annually. The company has a proven track record and extensive experience in the perishables sector, shipping various seasonal fresh products, including salmon, cherries, berries, and mangoes, to Asia and across the world. Additionally, they serve key industries, including automotive, high-tech, industrial, fashion, and retail.
Once the acquisition will be finalised, the two companies will greatly improve their complementary joint value proposition in the Americas. Apex’ established charter and commercial flight networks between Asia and North America, combined with Andes’ local talent and expertise, are designed to create strong logistics solutions maximizing the strategic potential within Latin America.
Mr. Tony Song, CEO of Apex Logistics Group, says: “This acquisition significantly enhances our presence in the region as part of our growth strategy in Latin America. Andes Integración Logística’s expertise in fresh and cold chain logistics supplements Apex’s investments in similar areas in North America very well. We will have a dedicated perishables team of over 100 professionals and expand our cold-chain warehousing capacity, which will include temperature-controlled facilities exceeding 60,000 square feet, across LAX and SFO. A fleet of more than 10 refrigerated trucks supports this expansion.”
Ms. Elsie Qian, CEO of Apex Logistics Americas, says: “With our strong customer proximity, relationship, and extensive operational experience in North America, the transaction and partnership with Andes Integración Logística will enable us to complement our customer’s service coverage into South America, broadening our regional network and unlocking exciting new growth opportunities.”
Andes Integración Logística will continue to be managed by its experienced leadership team while maintaining its independent operational capabilities. The global network, resources, and solutions of the Apex Logistics Group will support this.
As part of a joint branding initiative, it is foreseen that Andes Integración Logística will become Andes by Apex. This change will reflect the shared commitment of both companies to grow together as strategic partners.
The transaction is still subject to customary closing conditions and approval by the competent authorities.
Getty Images
